0001493152-19-019361.txt : 20191217 0001493152-19-019361.hdr.sgml : 20191217 20191217161517 ACCESSION NUMBER: 0001493152-19-019361 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191217 ITEM INFORMATION: Other Events FILED AS OF DATE: 20191217 DATE AS OF CHANGE: 20191217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adhera Therapeutics, Inc. CENTRAL INDEX KEY: 0000737207 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 112658569 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-13789 FILM NUMBER: 191289884 BUSINESS ADDRESS: STREET 1: 4721 EMPEROR BOULEVARD STREET 2: SUITE 350 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-578-5901 MAIL ADDRESS: STREET 1: 4721 EMPEROR BOULEVARD STREET 2: SUITE 350 CITY: DURHAM STATE: NC ZIP: 27703 FORMER COMPANY: FORMER CONFORMED NAME: Marina Biotech, Inc. DATE OF NAME CHANGE: 20100722 FORMER COMPANY: FORMER CONFORMED NAME: MDRNA, Inc. DATE OF NAME CHANGE: 20080610 FORMER COMPANY: FORMER CONFORMED NAME: NASTECH PHARMACEUTICAL CO INC DATE OF NAME CHANGE: 19920703 8-K 1 form8-k.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):

December 17, 2019

 

Adhera Therapeutics, Inc.

 

(Exact name of registrant as specified in its charter)

 

Delaware   000-13789   11-2658569
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

4721 Emperor Boulevard, Suite 350

Durham, North Carolina

  27703
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 919-578-5901

 

N/A

 

Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
__   __   __

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

   
 

 

Item 8.01 Other Events.

 

On December 17, 2019, Adhera Therapeutics, Inc. (the “Company”) determined that it would terminate its current business operations, including its commercial operations relating to the sale of its U.S. Food and Drug Administration approved product Prestalia® for the treatment of hypertension, and terminate the personnel associated with such operations, starting immediately. The Company expects to complete the foregoing actions on or prior to December 31, 2019. As a result of the termination of the Company’s current business operations, the distribution of Prestalia will be stopped, and Prestalia will no longer be available to patients in the United States.

 

The Company plans to actively work with its advisors to restructure the Company and to identify potential strategic transactions to enhance the value of the Company as such opportunities arise, including potential transactions involving the assets relating to the Company’s legacy RNA interference programs, as well as business combination transactions with operating companies.

 

   
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Adhera Therapeutics, Inc.
     
December 17, 2019 By: /s/ Nancy R. Phelan
  Name: Nancy R. Phelan
  Title: Chief Executive Officer